Targets › TIGIT
18 programs from 16 companies in 102 trials: 58 Phase 2, 23 Phase 3, 21 Phase 1; Oncology; next expected readout Nov 2026.
Inhibitory receptor that plays a role in the modulation of immune responses. Suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells. (UniProt, Q495A1)
Open in Phaseline: the race on TIGIT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Roche | Tiragolumab T-cell immunoreceptor with Ig and ITIM domains inhibitor | TIGIT | Phase 3 | Hepatocellular Carcinoma; Cancer; Renal Cell Carcinoma; Rectal Neoplasms … | Nov 2026 |
| AstraZeneca | Volrustomig (MEDI5752) CTLA-4/PD-1 bispecific antibody | CTLA4, PDCD1, TIGIT | Phase 3 | Metastatic Non-small Cell Lung Cancer; Locally Advanced Cervical Cancer; Unresectable Pleural Mesothelioma; Locally Advanced Head and Neck Squamous Cell Carcinoma … | Jan 2027 |
| Gilead Sciences | Domvanalimab T-cell immunoreceptor with Ig and ITIM domains inhibitor | TIGIT | Phase 3 | Non-small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Advanced Non-Small Cell Lung Cancer; Lung Cancer … | Mar 2027 |
| AstraZeneca | AZD2936 (rilvegostomig) Anti-TIGIT/anti-PD-1 bispecific antibody | TIGIT, PDCD1 | Phase 3 | Non-small Cell Lung Cancer; Biliary Tract Cancer; Endometrial Cancer; HER2-positive Gastric Cancer … | Mar 2027 |
| Summit Therapeutics | Ivonescimab Dose 1 TIGIT inhibitor | TIGIT, CTLA4 | Phase 3 | Non-Small Cell Lung Cancer; Metastatic Urothelial Carcinoma | Apr 2028 |
| Hebei Medical University Fourth Hospital | Iparomlimab CTLA-4 inhibitor | CTLA4, TIGIT | Phase 2 | Esophageal Squamous Cell Carcinoma (ESCC); AFP Gastric or Gastroesophageal Junction Adenocarcinoma; Colon Cancer | Dec 2026 |
| Qianfoshan Hospital | Adebelizumab TIGIT antagonist monoclonal antibody | TIGIT | Phase 2 | Extensive Small Cell Lung Cancer | Dec 2026 |
| M.D. Anderson Cancer Center | Etigilimab TIGIT inhibitor | TIGIT | Phase 2 | Ovarian Cancer | Feb 2027 |
| Shanghai Henlius Biotech | HLX53 Anti-TIGIT Fc fusion protein | TIGIT | Phase 2 | Carcinoma, Hepatocellular | Feb 2027 |
| Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Iparomlimab TIGIT inhibitor | TIGIT | Phase 2 | Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer | Aug 2027 |
| University of Texas Southwestern Medical Center | Ligufalimab (AK117) TIGIT inhibitor | TIGIT | Phase 2 | Advanced Hepatocellular Carcinoma | May 2029 |
| Hebei Medical University Fourth Hospital | Enlonstobart TIGIT antagonist monoclonal antibody | TIGIT | Phase 2 | Efficacy and Safety of Short-course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for pMMR Locally Advanced Rectal Cancer | Jun 2030 |
| SCRI Development Innovations, LLC | atigotatug TIGIT inhibitor | TIGIT | Phase 2 | Limited Stage Small Cell Lung Cancer | May 2032 |
| Arcus Biosciences | Domvanalimab T-cell immunoreceptor with Ig and ITIM domains inhibitor | TIGIT | Phase 2 | Gastrointestinal Tract Malignancies; Non Small Cell Lung Cancer | – |
| Xencor | vudalimab (XmAb20717) Bispecific monoclonal antibody targeting CTLA-4 and TIGIT | CTLA4, TIGIT | Phase 2 | Ovarian Cancer | – |
| Suzhou Suncadia Biopharmaceuticals | Adebelimab Anti-TIGIT antibody | TIGIT | Phase 1 | Recurrent or Metastatic Cervical Cancer | Jan 2027 |
| D3 Bio (Wuxi) | D3L-002 Bispecific antibody targeting TIGIT and PVRIG | TIGIT, PVRIG | Phase 1 | Advanced Solid Tumor | Nov 2027 |
| Shanghai Huaota Biopharmaceutical | HB0036 Anti-PD-L1 and anti-TIGIT bifunctional molecule | CD274, TIGIT | Phase 1 | Advanced Solid Tumor | – |
Non-small Cell Lung Cancer (5) Hepatocellular Carcinoma (4) Cancer (4) Endometrial Cancer (4) Non-Small Cell Lung Cancer (4) Gastric Cancer (4) Biliary Tract Cancer (3) Metastatic Colorectal Cancer (2) Metastatic Urothelial Carcinoma (2) Advanced Solid Tumor (2) Melanoma (2) Non Small Cell Lung Cancer (2)
mixed (8), antibody (7), small molecule (3)
AstraZeneca (2) Hebei Medical University Fourth Hospital (2) Roche (1) Summit Therapeutics (1) D3 Bio (Wuxi) (1) Gilead Sciences (1) SCRI Development Innovations, LLC (1) University of Texas Southwestern Medical Center (1) Shanghai Henlius Biotech (1) M.D. Anderson Cancer Center (1) Shanghai Huaota Biopharmaceutical (1) Qianfoshan Hospital (1) Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1) Xencor (1) Suzhou Suncadia Biopharmaceuticals (1) Arcus Biosciences (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.